2016
DOI: 10.1200/jco.2016.34.15_suppl.4047
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: Capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).

Abstract: Purpose We assessed the effectiveness of EOX (capecitabine, oxaliplatin and epirubicin) compared with XELOX (capecitabine and oxaliplatin) as preoperative chemotherapy for initially unresectable locally advanced gastric cancer.Methods This is a prospective observational study. Patients with unresectable locally advanced gastric cancer were performed EOX regimen or XELOX regimen at the discretion of the investigators. They were assessed for response every 2 cycles by CT (computed tomography) scan. A multidiscip… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 17 publications
0
2
0
Order By: Relevance
“…Blinded central radiology analysis confirmed that inclusion criteria reflected the pre-specified TNM definition of LAGC to minimize unmeasured confounding and treatment selection bias in these nonrandomized cohorts. NAC was permitted to emulate "real world" SOC treatment in accordance with published standardized regimens from landmark studies (4) or resulting modifications (28)(29)(30). Finally, robotic outcomes were analyzed according to intention to treat and spanned the entire learning curve to maximize early detection of serious, unanticipated adverse events associated with adoption of the new procedure.…”
Section: Discussionmentioning
confidence: 99%
“…Blinded central radiology analysis confirmed that inclusion criteria reflected the pre-specified TNM definition of LAGC to minimize unmeasured confounding and treatment selection bias in these nonrandomized cohorts. NAC was permitted to emulate "real world" SOC treatment in accordance with published standardized regimens from landmark studies (4) or resulting modifications (28)(29)(30). Finally, robotic outcomes were analyzed according to intention to treat and spanned the entire learning curve to maximize early detection of serious, unanticipated adverse events associated with adoption of the new procedure.…”
Section: Discussionmentioning
confidence: 99%
“…Some phase III studies have revealed that both adjuvant chemotherapy and radiochemotherapy were bene cial in preventing recurrence in D2resected GC patients with positive LNs [23,24]. The oxaliplatin combined with capecitabine (XELOX regimen) is commonly used as rst-line postoperative adjuvant chemotherapy, especially for LN-positive gastric cancer patients, with tolerable side effects (most AEs are grade I/II) and a survival bene t (25.4-29 mo) [25][26][27].…”
Section: Survival Analysismentioning
confidence: 99%